Skip to content

Exercise Following Autologous Peripheral Blood Stem Cell Transplantation

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00883961
Enrollment
60
Registered
2009-04-20
Start date
2009-12-31
Completion date
2011-09-30
Last updated
2009-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological Disease

Keywords

High-dose chemotherapy, Hematological neoplasties, Fatigue, Cancer, Exercise, Sport, Hematologic neoplastic disorders

Brief summary

The study evaluates the effects of a supervised exercise program on the physical performance, the mood and the complications of therapy in patients undergoing a high-dose chemotherapy followed by an autologous peripheral blood stem cell transplantation.

Interventions

OTHERSupervised exercise

The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-70 * Hematological disease * Treatment with high-dose chemotherapy followed by autologous stem cell transplantation * Understanding of written German

Exclusion criteria

* Cardiorespiratory, metabolical, osteoarticular or immunological diseases which can be aggravated by exercise * Pathological stress-ECG at admission

Design outcomes

Primary

MeasureTime frame
VO2maxAt recruitment and after 3 weeks

Secondary

MeasureTime frame
MoodAt recruitment and after 3 weeks
Duration of aplasia3 weeks
Complications during hospitalization3 weeks
Need for transfusion of platelets and red blood cells3 weeks

Countries

Germany

Contacts

Primary ContactFernando Dimeo, MD
fernando.dimeo@charite.de+493084452098

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026